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INTRODUCTION 
Diseases associated with some of the human herpes viruses have 
been recognized for centuries; these include fever blisters or herpes 
labialis, herpes genitalis, varicella and zoster. It is only within the 
past decade or two that the impact of these viruses in medicine has been 
appreciated. This increased interest'has led to new information on 
various aspects of human herpes viruses and their resultant diseases, 
such as their molecular and genetic basis, epidemiology, latency and 
oncogenesis, immunology, clinical spectrum, diagnosis, prevention and 
treatment. It is the latter area, prevention and treatment, that is of 
critical interest to many modern practitioners, since herpes simplex 
virus infections of the oral and genital areas are among the most 
common infectious illnesses involving human beings. Both primary and 
recurrent forms of these viral infections occur. 
The reported frequency of these disease entities varies sub-
stantially with age, socioeconomic class, geographic location and 
source of information. The estimated numbers of cases occurring an-
nually in the United States are as follows: primary herpes labialis -
500,000; recurrent herpes labialis - 98,000,000; primary herpes 
genitalis - 20,000-300,000; recurrent herpes genitalis - 200,000-
9,000,000."'" Data collected by the Centers for Disease Control over a 
13 
year period (1966—1979) indicate a two—fold increase in the number 
of consultations with physicians for herpes labialis infections and a 
2 
nine-fold increase for herpes genitalis infections. Although in the 
2 
normal host neither herpes labialis nor herpes genitalis is considered 
life-threatening, they are associated with psychological distress and 
physical discomfort. Immunocompromised hosts, especially cancer 
patients or those undergoing organ transplantation, suffer significant 
morbidity and mortality as the result of herpes virus infections. 
There is currently no consistently efficacious therapy for herpes 
infections. Although many different modalities have been tried, in-
cluding antiviral agents such as adenine arabinoside and idoxuridine, 
topical surfactants including diethyl ether and chloroform, immuno-
stimulators such as vaccines and photodynamic inactivation, none have 
met with great success. Arildone (WIN 3820), an aryloxyalkyl 1,3-
diketone, has antiviral activity against a broad range of human viruses. 
It inhibits both simple, non-enveloped RNA-containing viruses and large, 
3 
well-enveloped DNA-containing viruses. Its spectrum of activity in-
cludes herpes simplex viruses, Types 1 and 2, and picornaviruses 
4-6 
including polioviruses, Types 1 and 2, and rhinoviruses. Arildone 
has been shown to inhibit viral replication in vitro by preventing 
virion uncoating and is thought to interact with the icosahedral protein 
4 7 
capsid. ' The direct but reversible interaction with the capsid of the 
virions may prevent conformational changes necessary for the uncoating 
and subsequent release of the viral genome into the host cell. 
Arildone thereby prevents virus-induced inhibition of protein synthe-
4 
sis in the host cell. 
Arildone has been administered by various routes, including oral, 
intravenous, cutaneous and intravaginal routes, to laboratory animals 
to evaluate its disposition and toxicity. A vanishing cream formulation 
containing 8 percent arildone (w/w) was administered to mice 
3 
g 
intravaginally and topically to intact and abraded skin. To simulate 
conditions of clinical usage, the drug was inserted or applied five 
times daily for seven consecutive days. No adverse reactions were re-
ported as a result of the use of 8 percent arildone cream. Twenty 
immunocompromised patients received either 8 percent arildone cream or 
placebo cream topically four times daily for seven days on one of their 
forearms.^ They were also given a challenge dose within 30 days of 
their study period. None of the 20 patients experienced any cutaneous 
or systemic side effects. 
Vaginal and cutaneous trials carried out in experimental animals 
suggested that the cutaneous tolerance was satisfactory for an 8 per-
cent arildone (w/w) in a 90 percent dimethyl sulfoxide (DMSO), 10 
percent propyl ethylene glycol (PEG) 400 solution. This formulation 
will be referred to as 8 percent arildone DMSO solution hereafter in 
this paper. DMSO was chosen as the solvent for this formulation be-
cause of the rapidity, ease and completeness of absorption of DMSO 
11 12 
through the intact dermis and other membranes. ' The percutaneous 
absorption of a number of drugs is greatly enhanced when dissolved in 
13 
solvents containing 60 percent or more of DMSO. DMSO is reported 
to enhance the effectiveness of topical corticosteroids and idoxuridine 
13-2 
in the treatment of herpes simplex and varicella zoster infections. 
The present study was conducted to evaluate 8 percent arildone DMSO 
solution and the vehicle solution with regard to cutaneous and 
systemic tolerance and immediate and delayed hypersensitivity. 
MATERIALS AND METHODS 
Study Design and Randomization 
This study was conducted in a double-blind, randomized, parallel 
design. Both the test formulation (8 percent arildone DMSO solution) 
and the placebo control (vehicle solution) were colorless and supplied 
in identical dropper bottles. Randomization was accomplished through 
a random number generator. 
Patient Population 
Twenty adult patients who satisfied the inclusion criteria were 
selected for participation in the study. All patients were over 18 
years of age and any females of childbearing potential were using 
adequate contraception. Each patient* was hospitalized during the 
seven day trial and was available for follow-up challenge testing. 
All subjects had either a documented history of recurrent mucocutaneous 
herpes simplex or varicella zoster virus infections, or were at risk 
for developing such infections. Patients with active but localized 
viral infections were also admitted into the study. Subjects were 
immunocompromised as a result of advanced malignancy, primary con-
genital immune disorder, immunosuppressive therapy for organ trans-
plantation or radiation therapy for malignant disease or any other 
condition except collagen diseases. Agents employed in the immuno-
suppressive therapy included alkylating agents, antimetabolites, 
selected natural products, substituted ureas, methyl hydrazine de-
rivatives and selected hormones. 
Patient Exclusions 
Patients with a known hypersensitivity to arildone, DMSO or PEG 
400 were excluded from the study. Moribund patients or those with 
hepatic or renal impairment sufficient to alter metabolism or excretion 
of systemically absorbed drug were also excluded. Patients with severe 
or extensive skin disease of any etiology or those patients with 
septicemia, viremia or visceral viral'infection were not eligible for 
the study. Females of childbearing potential not practicing adequate 
contraception, patients with collagen vascular diseases or patients 
with cataracts were excluded from the study. 
Pretherapy Evaluation 
A complete review of systems, pertinent history and physical 
examination were performed on all patients during the week prior to 
commencement of topical therapy. Both the history and the physical 
examination stressed past and present cutaneous viral infections, 
past and present immunotherapy and history and present status of the 
disease for which the immunotherapy had been administered. A record 
of the patient's known sensitivities to medications and other aller-
gens, such as foods and soaps, was also obtained. The appearance of 
the healthy skin areas to which the test and vehicle formulations 
were to be applied was described 
prior to the initiation of the seven 
day course. A complete blood count with white cell differential, 
platelet and reticulocyte counts, methemoglobin, urinalysis and blood 
chemistries were obtained. The blood chemistries included calcium, 
phosphorous, glucose, uric acid, blood urea nitrogen (BUN), albumin, 
serum glutamic oxalacetic transaminase (SGOT), lactic dehydrogenase 
(LDH), alkaline phophastase, total protein, total bilirubin and choles-
terol levels. All signs and symptoms attributable to the patient's 
disease state or immunosuppressive therapy were also recorded during 
the pretreatment period. 
Topical Application 
One-half milliter of the test solution or vehicle solution was 
applied to either the left or right flexor forearm four times daily for 
seven consecutive days. Thus, the tcftal daily dose and the total 
cumulative dose for each patient was approximately 2 ml and 14 ml, 
respectively (or, in terms of arildone activity, 0.16 and 1.12 g, 
respectively). 
Each 0.5 ml of arildone DMSO solution was delivered by means of a 
calibrated dropper. The 0.5 ml dose was composed of 16 drops (± 1 
drop) when the dropper was held at an angle of 90 degrees to the flexor 
forearm plane. The drops were delivered from a distance of 1-2 cm and 
were placed 1-5 cm apart in two rows parallel to the long axis of the 
flexor forearm. The 16 drops were then distributed over the entire 
forearm surface. The person administering the drug wore a disposable 
surgical glove when applying the agent. No dressing was applied during 
or between doses. The test skin area was not washed or pretreated by 
any means prior to the application of succeeding doses. 
Cutaneous Tolerance 
The appearance of the forearm areas to which the test or vehicle 
formulations were applied was described daily by one of the two study 
team members. Erythema, drying, scaling, thickening, induration, 
vesiculation and ulceration were noted. Each patient was questioned 
7 
daily about any itching or burning associated with administration of the 
solution. These symptoms were graded by the subject as mild, moderate 
or severe. Onset, duration and severity of any of the above symptoms 
was noted. 
Systemic Tolerance 
Laboratory assessment of systemic tolerance involved repeating 
those tests described in the pretherapy evaluation on the fourth and 
seventh days of treatment. * 
Hypersensitivity 
Any immediate hypersensitivity reactions occurring during the 
seven day treatment period were noted. All patients were rechallenged 
with the same formulation they had received during the seven day 
course. These rechallenge doses were applied within 30 days of the 
termination of the one week study period. The formulation was applied 
to the same surface and in the same manner as during the previous 
seven day course. Single observations of this area were done 24 and 
48 hours later by the same study team member. The adverse reactions 
were graded in the same manner as those experienced during the seven 
day trial. 
Statistical Analysis 
For tolerance parameters, the null hypothesis was that there was no 
difference between the test preparations and the control formulation. 
Rejection of the null hypothesis would indicate that the two test 
formulations were not tolerated to the same extent. 
8 
A Chi-square statistic was used to test the hypothesis of an 
association between severity of side effects and the treatment groups. 
The absence of an association signifies that the distribution of 
adverse reactions is the same for the two treatment groups. 
The sample proportions in this study fit into contingency tables, 
therefore the Chi-square test is a test of homogeneity. In the case of 
one degree of freedom , the approximaXion of the discrete sampling dis-
tribution of the Chi-square was improved by applying a continuity or 
Yate's correction. When the observed frequencies were too small (less 
than 15 subjects total) for the sampling distribution of the Chi-
22 
square statistic, a Fisher's exact test of independence was used. 
To determine the significance of the changes in laboratory values, the 
23 
McNemar's test was used. 
RESULTS 
Twenty patients started the seven day course; fifteen of these 
subjects completed the study period. Patient characteristics are 
presented in Table 1. There were six male and four female subjects in 
the arildone solution group and five male and five female patients in 
the placebo vehicle group. Those subjects receiving the arildone DMSO 
solution had a mean age of 57.3 years while the DMSO vehicle group had 
a mean age of 58.3 years. All patients were immunosuppressed secondary 
to underlying malignancy or chemotherapy. 
Pretherapy Evaluation 
The major laboratory abnormalities present in both study groups 
were attributable to their underlying malignancies. Most patients had 
abnormally low hematocrits, hemoglobins and red blood cell counts; 
these were most likely secondary to their underlying disease states 
and chemotherapy. Seven patients exhibited high reticulocyte counts 
which were also probably due to their*underlying anemias. All patients 
had depressed white blood cell counts as a result of their immuno-
suppressive therapy. Elevated leukocyte counts were seen in the sub-
jects with leukemias. The low calcium, cholesterol, albumin and total 
protein values were explainable in light of the malnutrition that 
commonly accompanies malignancy. The two patients with prostate 
cancer had abnormally high alkaline phophatase levels as a result of 
their disease. All abnormalities found on physical examination were 
attributable to the patients' underlying disease processes or their 
therapy. 
Patient Tolerance 
Of the twenty patients who began the study, five did not complete 
the entire course of therapy because of severe adverse reactions. Two 
of these patients received 8 percent arildone DMSO solution while three 
were treated with the vehicle solution. The adverse reactions ex-
perienced by this group are summarized in Table 2. Of the remaining 
fifteen subjects who completed the seven day course, three did not 
develop side effects; all of these patients received the placebo formu-
lation. Twelve patients experienced mild to moderate adverse reactions 
which caused them some degree of discomfort, but it was not sufficient 
10. 
to necessitate discontinuing the study. Eight of these subjects re-
ceived 8 percent arildone DMSO solution while four received the vehicle 
solution. These results are presented in Table 3 which divides the 
patients into three groups - those who experienced no adverse reactions 
while in the study, those who experienced mild to moderate adverse 
reactions but completed the entire study period and those patients who 
did not finish the seven day trial secdrydary to severe adverse 
reactions. There were no statistically significant differences found 
between the group which received 8 percent arildone DMSO solution and 
the group which received the vehicle solution in regard to incidence of 
no adverse reactions (p > 0.1), mild to moderate adverse reactions 
» 
(p> 0.509) and severe adverse reactions (p> 0.6). 
All patients were divided into two groups, those who experienced 
adverse reactions (mild to moderate and severe) to their test formula-
tions and those who did not have any untoward side effects (Table 4). 
There were no significant differences between those patients who re-
ceived the active solution and those who received the vehicle solution 
(p> 0.8). 
The allergic histories of those patients who experienced adverse 
side effects from the topical formulations are presented in Table 5. 
A positive allergic history did not appear to influence a patient's 
tolerance of either the active agent or the placebo solution (p>0.3). 
The mild to moderate side effects experienced by 12 (60 percent) 
of the patients in this study are listed in Table 6. These 12 sub-
jects were grouped according to which formulation they received and 
which side effects they experienced. Both formulation groups were 
11 
compared within each side effect category. The differences in the 
rates of the adverse reactions were not statistically significant 
(p >0.4). 
The onset of the mild to moderate adverse reactions experienced 
by 12 patients is listed in Table 7. Although the data do not lend 
themselves to statistical analysis because of the small size and 
scattered nature of the numbers, it was, noted that 11 of the 12 
patients in this group experienced their initial side effects by 
the time 12 doses had been administered (within the first three days 
of therapy). The duration of the mild to moderate side effects noted 
by this group of patients was varied. Three patients in the group 
that received 8 percent arildone DMSO solution and one patient who 
received DMSO vehicle noted that their adverse side effects occurred 
for a time after each dose but were gone prior to the next application. 
Three subjects (one in the arildone DMSO group and two in the placebo 
group) experienced their adverse reactions without remission through 
the entire trial. The remaining five patients' (three in the arildone 
DMSO group and two in the DMSO solution group) side effects were 
initially self-limited but subsequently became continuous between doses 
for the remainder of the study. No patient's adverse reactions changed 
from a continuous to a self-limited nature during the seven day trial. 
Although statistical analysis cannot be applied to these data, there 
appear to be few differences between the group that received 8 percent 
arildone DMSO formulation and the group that received the DMSO vehicle. 
Even though eight of the 12 patients eventually experienced their 
symptoms continuously, these reactions were not severe enough to warrant 
cessation of the study. 
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The duration of the adverse reactions experienced by 17 patients 
after their study drugs were discontinued was varied. Of the five 
patients who developed side effects severe enough to cause their with-
drawal from the study (Table 2), three subjects continued to experience 
these adverse effects seven days after their last application. The 
other two patients had resolution of their symptoms within four hours 
of the last dose. Seven of the 12 patients who developed mild to 
moderate side effects were still experiencing these reactions after 
their last application (Table 8). The majority of these seven patients 
(six of the seven subjects) had complete resolution of all symptoms by 
the fourth day after the seven day trial. 
0 
Laboratory Parameters 
Changes in the status of each patient's laboratory values relative 
to baseline values were assessed by applying McNemar's test. These 
changes were considered relevant if the value altered from either low 
to normal or high to normal during the first four days or entire seven 
days of therapy. Within each individual parameter group, the number of 
increases was compared with the number of decreases for either the 8 
percent arildone DMSO group or the DMSO vehilce group. There were no 
statistically significant changes in any of the recorded laboratory 
values during the seven day application period. 
Hypersensitivity Reactions 
Rechallenge doses were administered within 30 days of the end of 
the treatment period to 13 patients. Two patients did not receive re-
challenge doses, one because of psychological deterioration and one be-
cause she was still experiencing adverse reactions from the original 
13 
drug applications. The three patients who experienced no adverse 
reactions during the seven day course also had no side effects with 
the rechallenge dose. Of the remaining 10 patients summarized in Table 
10, six also experienced no adverse reactions to the rechallenge dose. 
All of the adverse side effects secondary to the rechallenge were mild 
and abated within 24 hours. 
DISCUSSION 
Arildone is an effective antiviral agent in vitro and in laboratory 
animal studies. Its efficacy in human viral infections, especially 
human herpes simplex virus infections, is currently undergoing evalua-
tion. The formulation evaluated in this study was 8 percent arildone 
(w/w) in 90 percent DMSO 10 percent REG. The unique feature of DMSO 
which makes it an attractive topical vehicle is its ability to 
penetrate the skin. However, the cutaneous toxicities of the agent 
are appreciable. Reports of dermal toxicities in laboratory animals 
are varied. Although one investigator reported no skin irritation 
among guinea pigs painted with undiluted DMSO daily for 28 days, most 
investigators conducting repeated dose experiments with high concen-
trations of DMSO observed drying, scaling, erythema and eventual 
24~2 6 
desquamation of the treated skin. 
Studies of human volunteers have presented conclusive evidence 
that DMSO promotes the cutaneous penetration of a variety of substances 
but this phenomenon is most striking with concentrated solutions. Peak 
performance is achieved in solvents containing 80-90 percent DMSO. The 
percentage of human subjects showing an immediate-type of skin reaction 
to topical application of various concentrations of DMSO increases 
14 
proportionately with increasing concentration of the agent. Although 
48 percent of volunteers experienced immediate-type skin reactions with 
60 percent DMSO, 86 percent of the subjects reacted to 90 percent DMSO 
solution. Occasionally, erythema without healing results and sometimes 
27 
even the highest concentrations cause no adverse reactions. 
DMSO possesses potent histamine-liberating properties at the site 
of topical application. This histamine 'release develops swiftly and is 
manifested by a wheal and flare reaction when concentrations higher 
than 70 percent are applied under occlusion. The histamine release and 
increased vascular permeability are accompanied by vasodilation which 
appears to be the consequence of the exothermic association of DMSO 
9 
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and water. ' ' This response commonly occurs in the first week or 
<» 
two when DMSO is used once or twice daily, then disappears under con-
tinued application when the mast cell stores of histamine are 
depleted. 
The topical application of DMSO may lead to a series of derma-
tologic side effects including irritation, inflammation, burning, de-
22 25 27 
fatting, maceration and local dermatitis. ' ' The usual response 
to application of 70-90 percent DMSO applied twice daily is transient 
erythema, burning and itching. Continued use leads to mild scaling 
25 27 
of the skin and occasionally to continued dermatitis. ' A study 
of 1,097 orthopedic patients receiving daily applications of 90 percent 
DMSO best quantifies the incidence of dermatologic side effects as-
30 
sociated with single dose or short term use of the agent. Short term 
usage was defined as treatment of less than two weeks duration; the 
maximal daily dose was 10 ml of 90 percent DMSO. No local skin reaction 
15 
seen in 7.2 percent of the patients while 33 percent experienced a 
slight reaction (defined as warmth, itching and transient erythema). 
Fifty-six percent of the patients showed a "typical reaction" con-
sisting of burning, itching and erythema for three to four hours and 
occasional local urticaria. Severe reactions, local dermitis, urticaria 
and vesiculation, necessitating discontinuation of therapy, occurred 
in 3.5 percent of the cases. All reactions were independent of the 
patient's age and the intensity of the reaction was dependent on the 
type of skin and the area of application. These researchers found that 
the intensity of the adverse reaction changed from one application to 
another in those patients receiving 90 percent DMSO treatments longer 
than two weeks. Epidermal exfoliation and desquamation resolved com-
pletely within two weeks after discontinuation of therapy. 
The results of that investigation were similar to the present 
study except that our incidence of no adverse reactions and severe 
adverse reactions were larger than those observed in the earlier trial 
(15 percent vs. 7.2 percent, 25 percent vs. 3.5 percent). Respectively, 
our observed incidence of mild to moderate adverse reactions was lower 
than in the previous study (60 percent vs. 89.3 percent). The dis-
parities are probably due to a number of factors, the most significant 
of which are differences in study population size, underlying disorder 
and differences in application sites. Statistical analysis of the data 
generated in our study illustrated no significant difference between 
the groups receiving either the 8 percent arildone DMSO solution or the 
DMSO vehicle in regard to cutaneous or systemic tolerance. We conclude 
that all adverse reactions were secondary to the DMSO vehicle and not 
the active agent, arildone. The use of high concentrations (90 percent) 
16 
of DMSO to achieve marked dermal penetration most likely contributed to 
the cutaneous toxicities observed in this seven day trial. There was 
no statistically significant relationship between cutaneous tolerance 
of the DMSO vehicle and age, sex or past allergic history of the 
patient. 
Although DMSO is reported to cause side effects other than derma-
tologic, none of these were reported by ^ pur patients during their 
seven day study. Administration of DMSO results in a characteristic 
garlic-like taste and odor of the breath and skin. This is due to 
the dimethyl sulfide metabolite. This side effect was observed by 
the nursing staff administering the agent. Other known side effects 
not observed in our study include headache, nausea, diarrhea, burning 
on urination, transient disturbance of color perception and 
photophobia.^ 
Laboratory studies performed on 2,000 patients receiving chronic 
DMSO therapy (unspecified amounts for less than two years time) 
showed no significant abnormalities in SGOT, total protein, BUN, white 
blood cell count and differential, platelet count, bilirubin and 
31 
alkaline phophat 
ase. These tests were performed at unknown intervals. 
A previous investigation of the tolerance of 8 percent arildone cream 
found statistically significant alterations on serum calcium levels in 
some subjects. The clinical significance of this observation was not 
9 
determined. The present study found no significant abnormalities in 
laboratory parameters that may be attributed to either the active in-
gredient, arildone or the DMSO vehicle. 
The capacity of DMSO to promote the dermal penetration of many 
agents dissolved in the solvent is fascinating to many clinicians. One 
17 
of the proposed explanations for the lack of success with topically 
applied antiviral compounds is the failure of the drug to penetrate 
the skin and enter the cells in which the virus is replicating."'" 
Although DMSO in high concentrations may be effective in surmounting 
that barrier, the significant dermal toxicity associated with the 
compound should limit its use as a solvent at the present time. 
Additional clinical trials are needed to determine if the benefit 
of increased absorption of an antiviral compound dissolved in DMSO 
outweighs the short term risk of the adverse reactions associated with 
the use of the solvent. 
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Table 1. Patient Characteristics 
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AML = acute myelogenous leukemia 
CML = chronic myelocytic leukemia 
AIL = angio-immunoblastic lymphadenopathy 
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Table 2. The Severe Adverse Reactions Experienced by the Patients 
Who Did Not Complete the Seven Day Trial 
Patient 
Test 







after first dose 
90 minutes 
DMSO solution Severe burning, itching 
and vascular erythema 
progressing to papular 




DMSO solution Severe continuous erythema, 
mild itching and burning 





Severe burning, itching 8 days 
and moderate continuous 
erythema after 15 doses 
Severe continuous scaling, 7 days 
itching, mild erythema 
and drying after 19 doses 
* 
One patient treated with 1 percent hydrocortisone cream four 
times daily since drug was discontinued 









female male total female male total female male total 
DMSO solution 
12 
P > 0.1, Fischer's Exact P > 0.51, Fischer's Exact P > 0.6, Fischer's Exact 
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Table 4. Incidence of All Adverse Reactions Separated by 
Treatment Group 
No Adverse Adverse 
Reaction Reaction Total 
# 
8% arildone 
DMSO solution 0 • 10 10 
DMSO solution 3 7 10 
3 17 20 
P > 0.8, Chi-square 
23 
Table 5. Patients Who Experienced Adverse,Reactions and the 
Influence of Allergic History 
Positive Negative 
Allergic History Allergic History Total 
8% arildone 
DMSO solution 4 . 6 10 
DMSO solution 3 4 7 
7 10 17 
P > 0.3, Chi-square 
24 
Table 6. Mild to Moderate Adverse Reactions Experienced by 
Twelve Patients 
8% Arildone 
DMSO Solution * DMSO Solution Total 
n = 8 n = 4 n = 1 2 
Adverse Reaction 
• • 
Erythema 6 4 10 
Itching 4 3 7 
Burning 4 2 7 
Scaling 5 2 7 
Rash 2 1 3 
Induration 1 0 1 
Drying 1 1 2 
23 13 37 
P > 0.4, Chi-square 






A D A D A D A D A D A D 
n=6 n=4 n=4 n=3 n=4 n=2 n=5 n=2 n=2 n=l n=8 n=4 
0 - 4 4 1 2 2 1 1 . 0 0 0 7 4 
5 - 8 1 0 0 1 0 0 0 0 
\ 
0 0 1 1 
9 - 12 0 3 0 0 2 0 2 0 1 1 5 4 
13 - 16 0 0 0 0 0 1 1 1 0 0 1 2 
17 - 20 1 0 1 0 0 0 1 0 1 0 4 0 
21 - 24 0 0 0 0 0 0 1 1 0 0 1 1 
25 - 28 0 0 1 0 1 0 0 0 0 0 2 0 
A = 
D = 
8 percent arildone DMSO solution 
DMSO solution 
Table 8. Duration of Continuous Mild to Moderate Adverse Reactions Experienced by Seven Patients 
After Discontinuation of the Study Drugs 


























24 hours 0 1 0 0 0 0 0 0 
* 
1 0 1 1 
24-48 hours 0 1 0 0 0 0 0 0 \ 0 0 0 1 
3 days 1 0 1 0 0 0 3 1 0 0 5 1 
4 days 2 0 1 0 1 0 1 0 0 0 5 0 
5 days 0 0 0 0 0 0 0 0 0 0 0 0 
6 days 0 0 0 0 0 0 0 0 0 0 0 0 




1 0 3 
A = 8 percent arildone DMSO solution 
D = DMSO solution 
* = one patient treated with 1 percent hydrocortisone cream four times daily since drug was discontinued 
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Table 9. Response to Challenge Dose Among the Ten Patients Who 
Experienced Mild to Moderate Adverse Reactions During 
the Seven Day Trial 
8% Arildone^ 
Response DMSO Solution DMSO Solution Total 
No adverse reaction 
experienced within 
48 hours after 
challenge dose 
Adverse reaction 
lasted less than 
one hour 
Adverse reaction 
lasted 1-6 hours 
Adverse reactions 
lasted 6-12 hours 
Adverse reaction 
lasted 12-24 hours 
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